Sierzega Marek, Popiela Tadeusz, Kulig Jan, Nowak Krystyna
1st Department of Surgery, Jagiellonian University Medical College, Krakow, Poland.
Pancreas. 2006 Oct;33(3):240-5. doi: 10.1097/01.mpa.0000235306.96486.2a.
The aim of this study was to evaluate the prognostic value of nodal involvement in resected adenocarcinoma of the pancreatic head.
For the period between 1980 and 2002, 96 patients underwent pancreaticoduodenectomy for pancreatic cancer. Lymph nodes were numbered and classified into groups according to the Japan Pancreatic Society rules. Metastatic lymph nodes were identified based on hematoxylin and eosin staining.
Sixty-four (66.7%) patients had positive lymph nodes. The median number of metastatic nodes was 2 (95% confidence interval [CI], 1.0-3.0) and the median ratio of metastatic/resected nodes was 9.7% (95% CI, 7.1%-14.4%). The median survival was 14.2 months (95% CI, 10.7-17.7) and was significantly higher for node-negative than node-positive patients (27.9; 95% CI, 20.9-34.9 vs. 10.6; 95% CI, 8.7-12.5; P < 0.001). The Cox proportional hazards model, including all patients, demonstrated that nodal involvement (hazard ratio [HR], 1.461; 95% CI, 1.177-12.024), moderate or poor tumor differentiation (HR, 2.330; 95% CI, 1.181-6.949), and positive resection margins (HR, 3.838; 95% CI, 1.390-10.597) were independent negative prognostic factors. If the analysis was limited to node-positive patients, lymph node ratio of more than 20% (HR, 1.364; 95% CI, 1.116-2.599), moderate or poor tumor differentiation (HR, 3.393; 95% CI, 1.041-11.061), and positive resection margins (HR, 9.400; 95% CI, 2.235-39.536) significantly correlated with a poorer survival.
Lymph node ratio seems to be a new promising prognostic factor in patients with respectable node-positive pancreatic head cancer.
本研究旨在评估淋巴结受累情况对胰头切除腺癌的预后价值。
1980年至2002年期间,96例患者因胰腺癌接受了胰十二指肠切除术。根据日本胰腺学会的规则对淋巴结进行编号并分组。基于苏木精和伊红染色确定转移淋巴结。
64例(66.7%)患者有阳性淋巴结。转移淋巴结的中位数为2个(95%置信区间[CI],1.0 - 3.0),转移/切除淋巴结的中位数比例为9.7%(95% CI,7.1% - 14.4%)。中位生存期为14.2个月(95% CI,10.7 - 17.7),淋巴结阴性患者的中位生存期显著高于淋巴结阳性患者(27.9;95% CI,20.9 - 34.9对10.6;95% CI,8.7 - 12.5;P < 0.001)。包含所有患者的Cox比例风险模型表明,淋巴结受累(风险比[HR],1.461;95% CI,1.177 - 12.024)、中度或低分化肿瘤(HR,2.330;95% CI,1.181 - 6.949)以及切缘阳性(HR,3.838;95% CI,1.390 - 10.597)是独立的负面预后因素。如果分析仅限于淋巴结阳性患者,淋巴结比例超过20%(HR,1.364;95% CI,1.116 - 2.599)、中度或低分化肿瘤(HR,3.393;95% CI,1.04I - 11.061)以及切缘阳性(HR,9.400;95% CI,2.235 - 39.536)与较差的生存率显著相关。
淋巴结比例似乎是可切除的淋巴结阳性胰头癌患者一个新的有前景的预后因素。